AcelRx divests Dsuvia to Alora Pharmaceuticals

AcelRx announced the divestment of its FDA-approved drug, Dsuvia to Alora Pharmaceuticals. The agreement allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of Dsuvia. The agreement provides AcelRx with a 15% royalty on commercial sales of DSUVIA, a 75% royalty on sales of Dsuvia to the Department of Defense, Dsuvia’s single largest customer, and up to $116.5M in sales-based milestones. Closing of the transaction is expected by the end of the month, and AcelRx will provide, and be reimbursed for, transition services during a period of up to 6 months post-closing. In exchange for the 75% royalty on net sales to the DoD, AcelRx will lead the relationship to ensure continued engagement and expected expansion of sales to the DoD.